Opinion
Treatment with GLP-1 drugs must not replace obesity prevention in low and middle income countries
Prevention policies and budgets must be protected and aligned with the expansion of GLP-1 weight loss drugs, argue Kent Buse and colleagues The World Obesity Federation has welcomed the World Health ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results